2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Endogenous Metabolite
  5. Endogenous Metabolite Isoform
  6. Endogenous Metabolite Modulator

Endogenous Metabolite Modulator

Endogenous Metabolite Modulators (8):

Cat. No. Product Name Effect Purity
  • HY-124265R
    4β-Hydroxycholesterol (Standard)
    		Modulator
    4β-hydroxy Cholesterol (Standard) is the analytical reference standard of 4β-hydroxy Cholesterol (HY-124265). This product is used for research and analytical applications. 4β-Hydroxycholesterol is a major Cholesterol (HY-N0322) metabolite and a precursor in the synthesis of bile acids that is found in human circulation.
  • HY-18252R
    Avanafil (Standard)
    		Modulator
    Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
  • HY-18252S1
    Avanafil-13C5,15N,d2
    		Modulator
    Avanafil-13C5,15N,d2 is 15N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
  • HY-147406
    Tonlamarsen
    		Modulator
    Tonlamarsen is a angiotensinogen synthesis reducer, with antihypertensive activity.
  • HY-18252S3
    Avanafil-13C5
    		Modulator
    Avanafil-13C5 (TA1790-13C5) is 13C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
  • HY-165650A
    C16 Ganglioside GM1 (d18:1/16:0) ammonium
    		Modulator
    C16 Ganglioside GM1 (d18:1/16:0) (C16-GM1) ammonium is a member of the ganglioside family containing saturated C16:0 acyl chains. C16 Ganglioside GM1 (d18:1/16:0) ammonium serves as a functional receptor for Cholera toxin (HY-P1446) B subunit, while showing reduced efficiency in both transcytosis and retrograde pathways. C16 Ganglioside GM1 (d18:1/16:0) ammonium can be used for diarrheal diseases research.
  • HY-130285
    10(S),17(S)-DiHDHA
    		Modulator
    10(S),17(S)-DiHDHA (also known as neuroprotectin D1 when produced in neuronal tissues) is a DHA-derived dihydroxy fatty acid that exhibits potent protective and anti-inflammatory activities.
  • HY-18252S2
    Avanafil-d4
    		Modulator
    Avanafil-d4 (TA1790-d4) is deuterium-labeled Avanafil (HY-18252).